Compound | Name, Synonyms |
3-O-Ac-[18F]FcyF (10) | 3-O-[18F]acetylcyclofoxy, 3-O-Acetyl-6-deoxy-6-beta-[18F]fluoronaltrexone |
β-Endorphin | Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val- Thr-Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu CAS RN: [61214-51-5] |
BEMP | 2-tert-butylimino-2-diethylamino-1,3-dimethyl-perhydro-1,3,2-diazaphosphorine CAS RN: [98015-45-3] |
[11C]BPN (14) | [11C]buprenorphine, [6-O-methyl-11C]buprenorphine |
Caf | carfentanil, 1-(2-phenylethyl)-4-[(1-oxopropyl)phenylamino]-4-piperidine carboxylic acid methyl ester, R-31,833, 4-carboxymethyl-fentanyl, CAS RN: [59708-52-09] |
[11C]Caf (8) | [11C]carfentanil |
[3H]DAMGO | [3,5-3H]Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol |
DBU | 1,8-diazabicyclo[5.4.0]undec-7-ene, CAS RN: [6674-22-2] |
DIPEA | ethyldiisopropylamine, N,N-diisopropylamine, Hünig’s base |
DMF | N,N-dimethylformamide |
[11C]DPN (15) | [11C]diprenorphine, [6-O-methyl-11C]diprenorphine |
dppf | 1,1’-ferrocenediyl-bis(diphenylphosphine), CAS RN: [121450-46-8] |
Dynorphin A [1-17] | Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-T rp-Asp-Asn-Gln CAS RN: [80448-90-4] |
Dynorphin A [1-8] | Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile, CAS RN: [75790-53-3] |
Dynorpin B [1-13] | Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr, CAS RN: [83335-41-5] |
[11C]EKAP (27) | (R)-(methyl-11C) 4-(2-(3,4-dichlorophenyl)acetyl)-3-((diethylamino)methyl) piperazine-1-carboxylate |
cyF | cyclofoxy, 6-deoxy-6β-[18F]fluoro-naltrexone, N-cyclopropylmethyl-6-deoxy-6β-fluoro-noroxymorphone, 17-cyclopropylmethyl-4,5α-epoxy-6β-fluoro-morphinan-3,14-diol CAS RN: [103223-57-0] |
[18F]FcyF (11) | [18F]cyclofoxy, 6-Deoxy-6-β-[18F]fluoro-naltrexone, N-cyclopropylmethyl-6-deoxy-6β-[18F]fluoro-noroxymorphone, CAS RN: [103223-58-1] |
FDOPA | 6-fluoro-L-dopa, 2-Fluoro-5-hydroxy-L-tyrosine, CAS RN: [144334-59-8] |
[18F]FE-DPN (16) | 6-O-(2-[18F]fluoroethyl)-6-O-desmethyl-diprenorphine |
[11C]FEKAP (28) | (R)-(methyl-11C)4-(2-(3,4-dichlorophenyl)acetyl)-3-((ethyl(2-fluoroethyl)amino) methyl)piperazine-1-carboxylate |
[18F]FE-BPN (19) | 6-O-(2-[18F]fluoroethyl)-6-O-desmethyl-buprenorphine |
[18F]FP-norBPN (21) | N17-(3-[18F]fluoropropyl)-nor-buprenorphine |
[18F]FP-norDPN (20) | N17-(3-[18F]fluoropropyl)-nor-diprenorphine |
[18F]FE-NTI (23) | [18F]fluoroethyl-naltrindole, N1’-(2-[18F]Fluoroethyl)-naltrindole, [18F]BU97001 |
[18F]FE-PEO (17) | 6-O-(2-[18F]fluoroethyl)-6-O-desmethyl-phenethyl-orvinol |
[18F]FE-Tos | [18F]fluoroethyl tosylate |
Foxy | 6-deoxy-6β-fluoro-oxymorphone, «fluorooxymorphone », 4,5α-Epoxy -6β-fluoro-17-methyl-morphinan-3,14-diol, CAS RN: [92593-44-7] |
[3H]Foxy | [1,2-3H]-4,5α-epoxy-6β-fluoro-17-methyl-morphinan-3,14-diol, CAS RN: [96917-45-2] |
[11C]GR103545 (25) | [(3,4-dichlorophenyl)acetyl]-(3R)-(1-pyrrolidinylmethyl)-1-piperazine carboxylic acid methyl-11C ester |
[11C]GR89696 (26) | 4-[(3,4-dichlorophenyl)acetyl]-3-(R,S)-(1-pyrrolidinylmethyl)-1-piperazine carboxylic acid methyl-11C ester |
HD | Huntington’s disease |
[11C]LAAM (13) | N-(methyl-11C)-L-α-acetoxymethadol, N-(methyl-11C)-levo-alpha-acetyl methadol, N-(methyl-11C)-levomethadyl acetate |
Leu5-enkephalin | H-Tyr-Gly-Gly-Phe-Leu-OH, CAS RN: [58569-55-4] |
LY2459989 | 3-fluoro-4-[4-[[(2S)-2-(3-pyridyl)pyrrolidin-1-yl]methyl]phenoxy] benzamide |
LY2795050 | 3-chloro-4-[4-[[(2S)-2-(3-pyridyl)pyrrolidin-1-yl]methyl]phenoxy] benzamide, CAS RN: [1346133-08-1] |
LY2456302 (34) | (S)-4-(4-((2-(3,5-dimethylphenyl)pyrrolidin-1-yl)methyl)phenoxy)- 3-fluorobenzamide, CERC-501, CAS RN: [1174130-61-0] |
LY2940094 | ([2-[4-[(2-chloro-4,4-difluoro-spiro[5H-thieno[2,3-c]pyran-7,4′-piperidine]- 1′-yl)methyl]-3-methyl-pyrazol-1-yl]-3-pyridyl]methanol), BTRX-246040, CAS RN: [1307245-86-0] |
Met5-enkephalin | H-Tyr-Gly-Gly-Phe-Met-OH |
[11C]MeJDTic (29) | (3S)-7-hydroxy-N-((1S)-1-[[3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl- 1-piperidinyl]methyl]-2-methylpropyl)-2-[11C]methyl-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide |
[11C]MeNTI (22) | [11C]methyl-naltrindole, N1’-[11C]methyl-naltrindole |
[18F]MK-0911 (39) | 1-(2-[18F]fluoroethyl)-3-[(3R,4R)-3-(hydroxymethyl)-1-[[(8S)-spiro[2.5]octan-8-yl] methyl]piperidin-4-yl]benzimidazol-2-one |
MPTP | 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, CAS RN: [28289-54-5] |
Oxycodone | 14-hydroxy-dihydrocodeinone, CAS RN: [76-42-6] |
Naloxone |
N17-allyl-14-hydroxy-dihydromorphinone, N17-Allyl-noroxymorphone, CAS RN: [465-65-6] |
Naltrexone |
N17-cyclopropylmethyl-14-hydroxy-dihydromorphinone, N17-cyclopropylmethyl-noroxymorphone, NTX CAS RN: [16590-41-3] |
Nociceptine | Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gln |
N-substituted-
[11C]quinolinimide (24) |
6-(2-{2-[4-(4-fluorobutyl)-benzenesulfonyl]-1,2,3,4-tetrahydro-isoquinolin-1-yl} -ethyl)-2-[11C]methyl-pyrrolo[3,4-b]pyridine-5,7-dione |
NTI | naltrexone-indole, naltrindole, CAS RN: [111555-53-4] |
[11C]NOP-1A (36) | (2S)-2-[(2-fluorophenyl)methyl]-3-(2-fluorospiro[4,5-dihydro-thieno[2,3-c]pyran- 7,4'-piperidine]-1'-yl)-N-[11C]methyl-propanamide |
OR | opioid receptor |
[11C]PEO (18) | [11C]phenethyl-orvinol, [6-O-methyl-11C]phenethyl-orvinol |
PET | positron emission tomography |
Pd2dba3 | Pd2(dba)3, tris(dibenzylideneacetone)dipalladium, CAS RN: [51364-51-3] |
[3H]PL017 | [3,5-3H]Tyr-Pro-(NMe)Phe-d-Pro-NH2, 3-N-Me-Phe-[3H]morphiceptin, [3H] [MePhe3,D-Pro4]morphiceptin |
Salvinorin A | methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-acetyloxy-2-(furan-3-yl)-6a,10b-dimethyl- 4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate, CAS RN: [83729-01-5] |
TBDMS | tert-butyldimethylsilyl protecting group |
TDBPN | 3-O-trityl-6-O-desmethyl-buprenorphine, CAS RN: [157891-93-5] |
TDDPN | 3-O-trityl-6-O-desmethyl-diprenorphine, CAS RN: [157891-92-4], “Luthra-precursor”, TDDPN was the first product of the company ABX advanced biochemical compounds Biomedizinische Forschungsreagenzien GmbH, Radeberg in 1997 |
TDPEO | 3-O-trityl-6-O-desmethyl-phenethyl-orvionol, CAS RN: [1187551-69-4] |
U-50488 | 3,4-dichloro-N-methyl-N-[(1R,2R)-2-(1-pyrrolidinyl)cyclohexyl]- benzene acetamide, NIH10533, CAS RN: [67198-13-4] |